Resumo

CANCIANO CHIRINO, Ernesto et al. Metformin in clinical-metabolic control of middle-aged women with non alcoholic fatty liver disease. Rev Cubana Obstet Ginecol [online]. 2012, vol.38, n.4, pp. 521-529. ISSN 0138-600X.

Introduction: nonalcoholic fatty liver disease (NAFLD) reaches uncertain prevalence in middle-aged women, with few drug options available. Objectives: to conduct a study to demonstrate effectiveness of metformin in clinical and metabolic control in middle-aged women with NAFLD in the municipality of San Antonio de los Baños, Artemisa province from January 2009 to September 2011. It was analyzed hypertension control according to the development time, body mass index (BMI)/waist-hip ratio (CC), blood levels of cholesterol and triglycerides, final ultrasonographic evolution. Methods: test of triple-blind medication use. It was selected a list of random numbers of 200 women between 40-59 years, with ultrasound diagnosis of NAFLD. They were divided into two groups of 100 by lot: A (women who had metformin) and B (conventional treatment). Results: hypertensive patients prevailed (60.5 %), 59.7 % had controlled hypertension using metformin, regardless of duration of hypertension (p = 0.02 Z). Out of the total, 45.5 % had increased BMI and 59.5 % had waist-hip ratio > 0.85. in group A , 56 % was normal weight with increased waist-hip ratio and poor linear correlation between variables (0.3). Cholesterol and triglyceride had greater variability in those treated with metformin. In group A, 69 % improved by ultrasound (z = 2.49 p = 0.02), with no significant differences between classes. Absolute risk reduction (ARR) was 0.2 (CI 0.1-0.6), relative risk reduction RRR was 0.5 (CI 0.35 to 0.52) and the number of patients needed to treat (NNT) was 5 (CI 4.8 to 5.6).

Palavras-chave : fatty liver; middle-aged; women; metformin.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )